Skip to main content
VERTEX PHARMACEUTICALS INC / MA logo

VERTEX PHARMACEUTICALS INC / MA — Investor Relations & Filings

Ticker · VRTX ISIN · US92532F1003 LEI · 54930015RAQRRZ5ZGJ91 US Manufacturing
Open in API
Filings indexed 2,379 across all filing types
Latest filing 2026-05-14 Major Shareholding Noti…
Country US United States of America
Listing US VRTX

About VERTEX PHARMACEUTICALS INC / MA

https://www.vrtx.com/

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to discover, develop, and commercialize transformative medicines for serious diseases. The company is a leader in the field of cystic fibrosis (CF), having developed multiple therapies that treat the underlying cause of the disease for a significant portion of patients. Beyond its focus on CF, Vertex is advancing a research and development pipeline that includes potential treatments for other serious conditions such as sickle cell disease, beta-thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, and type 1 diabetes. The company's strategy is centered on a deep understanding of human biology to address the root cause of illness.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2026
Major Shareholding Notification
2026-05-14 English
S-8 POS
Regulatory Filings Classification · 80% confidence The text is very short (54 characters) and simply references an SEC Form S-8 (“S-8 POS 2013 Plan”) with no substantive financial data, just a link or header. Under the “menu vs meal” rule, this is an announcement of a regulatory filing rather than the full report itself. It does not fit any other specific category, so it falls under the fallback “Regulatory Filings.”
2026-05-13 English
S-8 POS
Share Issue/Capital Change Classification · 82% confidence The document text references “S-8 POS” and “2013 Plan,” indicating a Form S-8 post-effective amendment registering shares for an employee benefit plan. This is a share registration/issue filing, fitting the Share Issue/Capital Change category (SHA).
2026-05-13 English
S-8 POS
Share Issue/Capital Change Classification · 45% confidence The document text references an SEC Form S-8 registration (“S-8 POS 2013 Plan”), which is used to register new share issuances (shares to be issued under an employee benefit plan). This falls under announcements of new share issues or capital changes rather than a repurchase. Thus it best fits into the “Share Issue/Capital Change” category (SHA).
2026-05-13 English
S-8 POS
Share Issue/Capital Change Classification · 85% confidence The document text shows a Form S-8 post-effective amendment (“S-8 POS … 2013 Plan”), which is a Securities Act registration of shares under an employee plan. Such filings relate to new share issues or capital changes rather than an interim report or regulatory announcement. Therefore this fits the “Share Issue/Capital Change” category (SHA).
2026-05-13 English
S-8 POS
Share Issue/Capital Change Classification · 60% confidence The text refers to a Form S-8 “2013 Plan,” which is a registration statement for issuance of shares under an employee benefit plan. This is an announcement of a new share issue/capital change rather than a financial report, conference call, or insider transaction. Therefore it best fits the Share Issue/Capital Change category (SHA).
2026-05-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.